title: [Lung functioning changes of asthmatic adults in treatment with cromolyn sodium and beclomethasone].
abstract: BACKGROUND
  In asthmatic patients, besides symptoms, international guidelines recommend the measure of lung functioning tests as a parameter leading to diagnostic classification and evaluation of the treatment's effect.
  
  
  OBJECTIVE
  To determine the changes in the lung function of asthmatic adults in treatment with cromolyn sodium and beclomethasone.
  
  
  METHODS
  We made a clinical trial in adults with more than five years of persistent moderate asthma diagnosis. Before beginning the treatment there were carried out pulmonary function tests (PFR) with basal espirometry (prebeta2) and postbronchodilatador (posbeta2). To receive treatment, the patients were randomized in group A (beclomethasone), B (cromolyn sodium) and C (both medications). Treatment was completed by 6 months and at the end the spirometry was repeated. The results were analyzed with ANOVA, Student t and Mann-Whitney U tests according to the variables distribution.
  
  
  RESULTS
  In each group 15 patients were included. The age, the asthma evolution time and the gender relationship were without differences. The results of the PFR are described as the average of the differences among the initial values and those obtained six months later: FEF25-75: prebeta2: group A: 15.4, B: 3.6 and C: 13.8 (ANOVA, p < 0.01); posbeta2: group A: 11, B: 4.5 and C: 17.5 (ANOVA, p < 0.5). FEF50: pre32: group A: 8.4, B: 2.3 and C: 14.7 (ANOVA, p <0.5); posbeta2: group A: 0.2, B: 3.1 and C: 15.7 (ANOVA, p < 0.01). FEF75: prebeta2: group A: 8.4, B: 4.7 and C: 13.6 (ANOVA, p < 0.5); posbeta2: group A: 4.2, B: 6.7 and C: 19.4 (ANOVA, p < 0.01). The differences between groups were: FEF25-75: prebeta2: A vs B, p = 0.08; B vs C, p = 0.1 and A vs C, p = 0.5; posbeta2: A vs B, p = 0.06; B vs C, p = 0.005 and A vs C, p =0.2. VF50: prebeta2: A vs B, p = 0.1; B vs C, p = 0.02 and A vs C, p = 0.1; posbeta2: A vs B, p = 0.4; B vs C, p = 0.001 and A vs C, p = 0.008. VF75: prebeta2: A vs B, p = 0.4; B vs C, p =0.03 and A vs C, p = 0.08; posbeta2: A vs B, p = 0.1; B vs C, p = 0.02 and A vs C, p =0.003.
  
  
  CONCLUSIONS
  In the asthmatic adult of long evolution, the inhaled treatment with cromolyn sodium improves the pulmonary function. That improvement is better with the use of beclomethasone, but the combined use improves even more the spirometry parameters.
authors.affiliation: Clínica de asma y alergia, Hospital General de Zona núm. 30, Iztacalco. ricardorguez1405@hotmail.com
authors.forename: Ricardo
authors.initials: R
authors.lastname: Rodríguez Medina
authors.forename: Martha Roxana
authors.initials: MR
authors.lastname: Gasca Bauza
authors.forename: José Luis
authors.initials: JL
authors.lastname: López Durán
authors.forename: Elia
authors.initials: E
authors.lastname: Zamora Limón
mesh_terms: D000328:Adult; D000420:Albuterol; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001507:Beclomethasone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001993:Bronchodilator Agents; D004205:Cromolyn Sodium / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005540:Forced Expiratory Flow Rates; D006801:Humans; D008297:Male; D008875:Middle Aged; D013147:Spirometry; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D001507:Beclomethasone; D004205:Cromolyn Sodium; D000420:Albuterol